Prospective studies | ||||||
---|---|---|---|---|---|---|
Study | n | Mean age | Mean baseline VA (ETDRS letters) | Visual change (ETDRS letters) | Number of injections | Treatment näive |
Ohji et al. (ALTAIR) [19] | 124a | NA | NA | + 9.0 (1y) | 7.2 | Yes |
123b | NA | NA | + 8.4 (1y) | 6.9 | ||
Haga et al. [6] | 21 | 75.5 | 56.9 | + 15.9 (1y) | 7.5 | NR |
DeCroos et al. (ATLAS) [5] | 35 | 81.3 | 58.9 | + 7.2 (1y) | 8.0 | Yes |
Hatz et al. [20] | 33 | 81.0 | 66.8 | − 0.6 (1y) | NR | No |
Jørstad et al. [21] | 50 | NR | 72.5g | + 0.5(1y)g | 9.2 | No |
Retrospective studies | ||||||
---|---|---|---|---|---|---|
Study | n | Mean age | Mean baseline VA (ETDRS letters) | Mean visual gain (ETDRS letters) | Number of injections | Treatment näive |
Barthelmes et al. [7] | 136 | 77.2 | 61.4 | + 6.0 (2y) | 13.6 | Yes |
Matsumoto et al. [8] | 18c | 75.7 | 53.5g | + 9.5 (1y)g | 7.7 | Yes |
44d | 71.5 | 72.0g | + 7.0 (1y)g | 8.3 | Yes | |
58e | 72.4 | 71.5g | + 8.0 (1y)g | 7.7 | Yes | |
5f | 77.2 | 56.5g | + 14.5 (1y)g | 7.3 | Yes | |
Matsumoto et al. [9] | 60 | 75.1 | 69.5g | + 9.0 (1y)g | 13.8 (2y) | Yes |
Ohnaka et al. [10] | 36 | 72.3 | 61.0g | + 4 (1y)g | 4.5 | Yes |
Yamamoto et al. [11] | 67 | NA | 70.5g | + 7.5 (1y)g | 8.3 | NA |
Ito et al. [12] | 61 | NA | NA | + 6.5 (2y)g | 13.6 | Yes |
Castro-Navarro et al. [13] | 30 | 78.8 | 54.5g | + 11.5 (1y)g | 7.7 | Yes |
Unsal et al. [14] | 38 | 74.5 | 39.1 | + 15.9 (1y) | 4.9 | Yes |
Ishibashi et al. [15] | 39 | 75.5 | 63.9 | + 6.5 (1y) | 7.9 | Mixed |
Wakuta et al. [16] | 16 | 78.3 | 65 | 0 (1y) | 7.8 (1y) | Mixed |
Current Study | 213 | 80.4 | 40.0 | + 10.1 (1y) | 7.4 | Yes |